Compare Citius Pharmaceuticals Inc (CTXR) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Solaredge Technologies Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Solaredge Technologies Inc trades at $32.08 (market cap $2.00B). The key difference: Solaredge Technologies Inc is far larger — about 146.8× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 2,739,860). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Solaredge Technologies Inc for 34 Days on average.
| CTXR | SEDG | |
|---|---|---|
Market Cap | $13.62M | $2.00B |
Volume | 132,438 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $1.82 | $78.51 |
52-Week Low | $0.48 | $28.47 |
Typical Hold Time | 17 Days | 34 Days |
Enterprise Value | $3.79M | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
SolarEdge Technologies (SEDG) trades at $32.21, down 2.86% on the day, amid a bearish technical signal and mixed earnings performance. The company reported a net loss of $405.45M in 2025, with negative profit margins, though revenue grew to $1.18B. Recent news highlights legal investigations and volatility driven by solar sector pressures and new AI data center initiatives announced in September 2026.
The outlook remains cautious due to persistent losses and high debt, but analyst consensus suggests moderate upside to a $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures, and reliance on solar market recovery. Investment appeal hinges on execution of growth targets and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
